A Phase II Open-Label Multicenter Randomized Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Brief description of study

This is a study testing two different treatments for patients with pancreatic cancer after surgery. The study team want to see if adding two drugs, autogene cevumeran and atezolizumab, to the usual treatment (mFOLFIRINOX) helps patients more than just getting mFOLFIRINOX. First the study team will check if patients qualify for the study based on specific requirements. Then, they will randomly assign patients to get either the new treatment or the regular one. The study will go on until they see if the cancer comes back, if there's a new cancer, or if the treatment is causing too many problems.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.